The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Mechanism of action of the hypnotic zolpidem in vivo
Open accessAbstract
Zolpidem is a widely used hypnotic agent acting at the GABA A receptor benzodiazepine site. On recombinant receptors, zolpidem displays a high affinity to α1‐GABA A receptors, an intermediate affinity to α 2‐ and α 3‐GABA A receptors and fails to bind to α 5‐GABA A receptors. However, it is not known which receptor subtype is essential for mediating the sedative‐hypnotic action in vivo. Studying α1(H101R) mice, which possess zolpidem‐insensitive α 1‐GABA A receptors, we show that the sedative action of zolpidem is exclusively mediated by α 1‐GABA A receptors. Similarly, the activity of zolpidem against pentylenetetrazole‐induced tonic convulsions is also completely mediated by α 1‐GABA A receptors. These results establish that the sedative‐hypnotic and anticonvulsant activities of zolpidem are due to its action on α 1‐GABA A receptors and not on α 2‐ or α 3‐GABA A receptors. British Journal of Pharmacology (2000) 131, 1251–1254; doi:10.1038/sj.bjp.0703717
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Nonparametric Statistics
Groggel, D. J. (2000) · Technometrics · doi:10.1080/00401706.2000.10486067 · Cited by 11,041
Handbook of experimental pharmacology
(1984) · International Journal of Biochemistry · doi:10.1016/0020-711x(84)90023-5 · Cited by 1,417
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
Self-citationMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
γ‐Aminobutyric AcidA Receptor α5‐Subunit Creates Novel Type II Benzodiazepine Receptor Pharmacology
Pritchett, D. B., & Seeburg, P. H. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01237.x · Cited by 503
Kupfer, D. J., & Reynolds, C. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360506 · Cited by 287
Lippa, A. S., Coupet, J., Greenblatt, E. N., Klepner, C. A., & Beer, B. (1979) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(79)90304-6 · Cited by 283
Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.
Depoortere, H., Zivkovic, B., Lloyd, K. G., Sanger, D. J., Perrault, G., Langer, S. Z., & Bartholini, G. (1986) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24899-6 · Cited by 282
Novel anxiolytics that act as partial agonists at benzodiazepine receptors
Haefely, W., Martin, J. R., & Schoch, P. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90126-s · Cited by 276
Self-citationArbilla, S., Depoortere, H., George, P., & Langer, S. Z. (1985) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00572441 · Cited by 169
Cited by
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1430 · Cited by 1,239
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes
Rudolph, U., & Knoflach, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3502 · Cited by 733
“Indeed, in α1(H101R) mice the motor sedative action of zolpidem was abolished, which demonstrates that the sedative action of zolpidem is mediated by α1-containing GABA A receptor”
BackgroundSelf-citationA new benzodiazepine pharmacology
Möhler, H., Fritschy, J. M., & Rudolph, U. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.2 · Cited by 716
Self-citationRudolph, U., & Möhler, H. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121429 · Cited by 519
Self-citationGABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
Self-citationGABAA receptor subtypes: dissecting their pharmacological functions
Rudolph, U., Crestani, F., & Möhler, H. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01646-1 · Cited by 471
Self-citationSleeping with the hypothalamus: emerging therapeutic targets for sleep disorders
Mignot, E., Taheri, S., & Nishino, S. (2002) · Nature Neuroscience · doi:10.1038/nn944 · Cited by 353
Diverse mechanisms of antiepileptic drugs in the development pipeline
Rogawski, M. A. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.02.004 · Cited by 340
GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery?
Whiting, P. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02703-x · Cited by 326
Sedation and Anesthesia Mediated by Distinct GABA A Receptor Isoforms
Reynolds, D. S., Rosahl, T. W., Cirone, J., O'Meara, G. F., Haythornthwaite, A., Newman, R. J., Myers, J., Sur, C., Howell, O., Rutter, A. R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08608.2003 · Cited by 318
Structure, Pharmacology, and Function of GABAA Receptor Subtypes
Sieghart, W. (2006) · Advances in Pharmacology · doi:10.1016/s1054-3589(06)54010-4 · Cited by 317
Greenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
GABAA Receptor Channel Pharmacology
Johnston, G. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054021024 · Cited by 274
Allain, H., Bentu??-Ferrer, D., Polard, E., Akwa, Y., & Patat, A. (2005) · Drugs & Aging · doi:10.2165/00002512-200522090-00004 · Cited by 214
“[84] fractures in the elderly.”
Kralic, J. E., O’Buckley, T. K., Khisti, R. T., Hodge, C. W., Homanics, G. E., & Morrow, A. L. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00174-0 · Cited by 168
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Antiepileptic drugs and the developing brain
Kaindl, A. M., Asimiadou, S., Manthey, D., Hagen, M. V. D., Turski, L., & Ikonomidou, C. (2006) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s00018-005-5348-0 · Cited by 121
Instructing Perisomatic Inhibition by Direct Lineage Reprogramming of Neocortical Projection Neurons
Ye, Z., Mostajo-Radji, M. A., Brown, J. R., Rouaux, C., Tomassy, G. S., Hensch, T. K., & Arlotta, P. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.006 · Cited by 73
“Therefore, we recorded mIPSCs before and after application of the GABRA1 agonist Zolpidem, which prolongs the opening of GABRA1 receptors (Crestani et al., 2000).”
Cheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
“Furthermore, α 1 subtype inactive compounds such as TPA023 show almost no abuse properties.(60) Recently, opposing evidence has shown that α 2 and α 3”
Sleep EEG changes after zolpidem in mice
Kopp, C., Rudolph, U., & Tobler, I. (2004) · NeuroReport · doi:10.1097/00001756-200410050-00031 · Cited by 66
Self-citationThe Non-Benzodiazepine Hypnotic Zolpidem Impairs Sleep-Dependent Cortical Plasticity
(2008) · Sleep · doi:10.5665/sleep/31.10.1381 · Cited by 60
Griebel, G., Perrault, G., Simiand, J., Cohen, C., Granger, P., Decobert, M., Françon, D., Avenet, P., Depoortere, H., Tan, S., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29437-4 · Cited by 59
Reynolds, L. M., Engin, E., Tantillo, G., Lau, H. M., Muschamp, J. W., Carlezon, W. A., & Rudolph, U. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.115 · Cited by 49
Self-citationUygun, D. S., Ye, Z., Zecharia, A. Y., Harding, E. C., Yu, X., Yustos, R., Vyssotski, A. L., Brickley, S. G., Franks, N. P., & Wisden, W. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3714-15.2016 · Cited by 48
“Zolpidem works at three GABAA receptor subtypes: 1 2, 2 2, and 3 2 (Pritchett and Seeburg, 1990; Crestani et al., 2000; Cope et al., 2004; Kopp et al., 2004; Leppä et al., 2011), and has the highest affinity at 1-containing receptors (Pritchett and Seeburg, 1990).”
BackgroundHeldt, S. A., & Ressler, K. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0693-10.2010 · Cited by 42
Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
Yen, C.-F., Ko, C.-H., Chang, Y.-P., Yu, C.-Y., Huang, M.-F., Yeh, Y.-C., Lin, J.-J., & Chen, C.-S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12147 · Cited by 22
Metadata
- Authors
- Crestani, F., Martin, J. R., Möhler, H., & Rudolph, U.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 131
- Issue
- 7
- Pages
- 1251-1254
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2162515150
- Cited by
- 307
- References
- 13
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.